网络教育对肠易激综合征不劣于小组面授教育:随机试验与患者偏好试验
在瑞典消化科门诊开展两项试验,比较网络授课与面授小组教育(3周)对肠易激综合征(IBS)的疗效。随机试验141例,偏好试验155例。主要终点为IBS严重程度评分(0-500)6个月内变化,非劣效界值40分。随机试验中面授组比网络组多降低12.2分(单侧95%CI上限38.4),符合非劣效;面授可信度和知识提升更优,但多数患者偏好网络教育。
要点
- 网络教育对IBS症状改善不劣于面授小组教育,6个月内评分差异的95%CI上限未超过40分非劣效界值。
- 面授教育的可信度更高且自评知识提升更显著,但多数患者仍偏好网络教育。
- 两组对次要症状的组间效应较小,未来研究应关注提升组内效应。
核心结论
- 网络教育对IBS的疗效不劣于面授小组教育,6个月内IBS严重程度评分变化差异的单侧95%CI上限38.4分,低于40分非劣效界值。
研究设计与样本
- 在瑞典一家消化科门诊开展两项试验:第一项为随机对照试验,141例IBS患者按1:1随机分配至网络教育或面授教育(2016年8月至2017年6月)。
- 第二项为患者偏好试验,155例IBS患者自行选择网络或面授教育(2017年8月至2018年9月)。
- 教育疗程均为3周,主要终点为IBS严重程度评分(0-500分)在教育后6个月内的变化,非劣效界值为40分。
主要发现
- 随机试验意向性分析中,面授组IBS严重程度评分平均降低比网络组多12.2分(单侧95%CI上限38.4分)。
- 符合方案分析中,面授组评分平均降低比网络组多14.7分(95%CI上限35.5分)。
- 面授教育的可信度显著更高,自评知识提升显著更大,但多数患者偏好网络教育。
- 两组对次要症状的组间效应较小。
关键数值与推荐
- 非劣效界值为IBS严重程度评分40分。
- 随机试验主要分析:面授组比网络组多降低12.2分(单侧95%CI上限38.4分),符合非劣效。
- 符合方案分析:面授组比网络组多降低14.7分(95%CI上限35.5分),符合非劣效。
临床怎么用
- 网络教育可作为IBS结构化教育的替代方式,便于推广且多数患者偏好。
- 面授教育在提升可信度和自评知识方面更优,可根据患者偏好和资源选择教育形式。
- 未来需研究如何提升教育组内效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Structured education can reduce symptoms in patients with irritable bowel syndrome (IBS), but the availability of such interventions is limited and online formats could facilitate their dissemination. We compared the effectiveness of Internet-delivered vs face-to-face education in patients with IBS, hypothesizing that the online format would not be inferior. METHODS: We conducted 2 trials of Internet-delivered vs face-to-face group education (3 weeks) at a gastroenterology outpatient clinic in Sweden. In the first trial, 141 patients with IBS were assigned randomly (1:1) to either Internet-delivered or face-to-face education, from August 2016 through June 2017. In the second trial, 155 patients with IBS were allowed to choose whether to receive education via the Internet or face to face, from August 2017 through September 2018. Patients completed questionnaires before, during, and after education. The primary outcome measure was the irritable bowel syndrome severity scoring system, which measures IBS severity on a scale from 0 to 500, based on abdominal pain, bloating, dissatisfaction with bowel habits, and interference with life. The primary test of noninferiority adhered to the intent-to-treat principle and concerned the difference in change up to 6 months after education, tested using the 1-sided CI for the time by group interaction in a linear mixed model fitted on data from the randomized controlled trial. A secondary per-protocol analysis used data from all treatment completers in both trials. The noninferiority margin was 40 points on the irritable bowel syndrome severity scoring system. RESULTS: In the primary analysis, patients who received face-to-face education had an average reduction in irritable bowel syndrome severity score that was 12.2 points more than that of patients who received Internet education (1-sided 95% CI upper bound, 38.4). In the per-protocol analysis, patients who received face-to-face education reduced their average irritable bowel syndrome severity score by 14.7 points more than patients who received Internet education (95% CI upper bound, 35.5). Face-to-face education had significantly higher credibility and produced a significantly larger increase in self-rated knowledge, although most patients preferred Internet-delivered education. Between-group effects on secondary symptoms were small. CONCLUSIONS: Based on the comparison of Internet-delivered vs face-to-face education for IBS, the upper bound of the CI for the difference in change up to 6 months after education was within the noninferiority margin of 40 points. We therefore conclude that Internet-delivered education is noninferior to face-to-face education. Future research should focus on increasing within-group effects. ClinicalTrials.gov no: NCT03466281.
引用
- Lindfors P, Axelsson E, Engstrand K, et al. Online Education Is Non-Inferior to Group Education for Irritable Bowel Syndrome: A Randomized Trial and Patient Preference Trial. Clin Gastroenterol Hepatol. 2020. PMID: 32289541. doi:10.1016/j.cgh.2020.04.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。